Tier 1 — highest

Single Center, Open-Label, Randomized Crossover Trial on Drug-Drug Interactions of Levothyroxine/Magnesium-Citrate and Levothyroxine/Magnesium-Aspartate in Healthy Subjects-The ThyroMag Trial

Martin Christian Attinger, Stefanie von Felten, Claudia Lourenço Rodrigues, Jan Krützfeldt, Lorenz Risch, Jérôme Bonzon
Clinical and translational science 2025 18(11):e70409

Bibliography

PubMed
PMID 41221788
PubMed Central
PMC12605969
DOI
10.1111/cts.70409
Funding
Funding is not specified in the indexed abstract or accessible funding metadata. Consult the original publication for the declaration.
Competing interests
The authors report no relevant competing interests.

Study snapshot

DesignOpen-label, randomized, three-period crossover pharmacokinetic trial
ModelHuman participants
Sample15 healthy euthyroid adults
InterventionLevothyroxine 1 mg alone or with magnesium citrate/aspartate formulations
DurationSingle-dose periods with 6-hour pharmacokinetic monitoring
EndpointsThyroxine exposure; Peak concentration; Time to peak

What the study showed, in plain terms

This publication examines thyroxine exposure, peak concentration, time to peak. Study population or evidence base: 15 healthy euthyroid adults. Intervention or exposure: Levothyroxine 1 mg alone or with magnesium citrate/aspartate formulations.

Key findings

Co-administered magnesium aspartate reduced thyroxine exposure; citrate produced a smaller, nonsignificant reduction. The study supports separating magnesium and levothyroxine administration.

What this study can and cannot tell us

Small acute study in healthy volunteers using specific formulations and a test dose of levothyroxine. It does not quantify long-term TSH effects in treated patients.

Citation network

Articles citing this research paper

3 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Biohack Blueprint Research